Following a negative FDA advisory committee vote earlier this year, the other shoe has dropped for Lundbeck and Otsuka Pharmaceutical’s post-traumatic stress disorder (PTSD) hopeful. The FDA has ...
The FDA is raising efficacy questions over Lundbeck and Otsuka’s proposed combination of their Rexulti with Viatris’ Zoloft as a treatment for post-traumatic stress disorder (PTSD). For an upcoming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results